Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study.

Journal:

Hepatology

Published:

2025-07-29

DOI:

10.1097/hep.0000000000001475

Affiliations:

26

Authors:

30

Go to article

Institutions	Authors	Share
Beijing Friendship Hospital, Capital Medical University, China	4.000000	0.13
Shenzhen Chipscreen Biosciences Co., Ltd., China	3.000000	0.10
The Affiliated Hospital, Hangzhou Normal University, HZNU, China	1.000000	0.03
The Second Hospital of Nanjing, China	1.000000	0.03
The Third Hospital of Hebei Medical University, HEBMU, China	1.000000	0.03
Beijing Youan Hospital, China	1.000000	0.03
Shanghai Tongren Hospital, SJTU, China	1.000000	0.03
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China	1.000000	0.03
Zhenjiang Third People's Hospital, China	1.000000	0.03
The First Affiliated Hospital, SYSU, China	1.000000	0.03
General Hospital of Ningxia Medical University, China	1.000000	0.03
The First Affiliated Hospital, Zhejiang University School of Medicine, China	1.000000	0.03
Peking University People's Hospital, PKUHSC, China	1.000000	0.03
First Hospital of Lanzhou University, LZU, China	1.000000	0.03
First Affiliated Hospital, ZZU, China	1.000000	0.03
The First Hospital of Jilin University, China	1.000000	0.03
The Fourth Affiliated Hospital of China Medical University, China	1.000000	0.03
First Affiliated Hospital, AHMU, China	1.000000	0.03
Shunde Hospital, SMU, China	1.000000	0.03
The Sixth People's Hospital of Shenyang, China	1.000000	0.03
The First Affiliated Hospital of Fujian Medical University, China	1.000000	0.03
Henan Provincial People's Hospital, China	1.000000	0.03
Shanghai Ninth People's Hospital, SJTU, China	1.000000	0.03
Foshan First People's Hospital, China	1.000000	0.03
Qingdao Municipal Hospital Group, China	0.500000	0.02
Qingdao University (QU), China	0.500000	0.02

Interested in Clinical Sciences?